BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 1701676)

  • 1. Characterization of the L-arginine:nitric oxide pathway in human platelets.
    Radomski MW; Palmer RM; Moncada S
    Br J Pharmacol; 1990 Oct; 101(2):325-8. PubMed ID: 1701676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of N-iminoethyl-L-ornithine as an irreversible inhibitor of nitric oxide synthase in phagocytic cells.
    McCall TB; Feelisch M; Palmer RM; Moncada S
    Br J Pharmacol; 1991 Jan; 102(1):234-8. PubMed ID: 1710525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo.
    Rees DD; Palmer RM; Schulz R; Hodson HF; Moncada S
    Br J Pharmacol; 1990 Nov; 101(3):746-52. PubMed ID: 1706208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin increases guanosine-3',5'-cyclic monophosphate in human platelets. A mechanism involved in the insulin anti-aggregating effect.
    Trovati M; Massucco P; Mattiello L; Mularoni E; Cavalot F; Anfossi G
    Diabetes; 1994 Aug; 43(8):1015-9. PubMed ID: 7518780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation.
    Radomski MW; Palmer RM; Moncada S
    Proc Natl Acad Sci U S A; 1990 Jul; 87(13):5193-7. PubMed ID: 1695013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-acetyl-L-cysteine exerts direct anti-aggregating effect on human platelets.
    Anfossi G; Russo I; Massucco P; Mattiello L; Cavalot F; Trovati M
    Eur J Clin Invest; 2001 May; 31(5):452-61. PubMed ID: 11380598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulation of cyclic GMP production in cultured endothelial cells of the pig by bradykinin, adenosine diphosphate, calcium ionophore A23187 and nitric oxide.
    Boulanger C; Schini VB; Moncada S; Vanhoutte PM
    Br J Pharmacol; 1990 Sep; 101(1):152-6. PubMed ID: 2178013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective effects of inhibitors of nitric oxide synthase in immune complex-induced vasculitis.
    Mulligan MS; Moncada S; Ward PA
    Br J Pharmacol; 1992 Dec; 107(4):1159-62. PubMed ID: 1281719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of L- and D-arginine and some related esters on the cytosolic mechanisms of alpha-thrombin-induced human platelet activation.
    Failli P; Cecchi E; Ruocco C; Fazzini A; Giotti A
    Br J Pharmacol; 1993 Sep; 110(1):213-8. PubMed ID: 8220881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of nitric oxide synthesis in the regulation of coronary vascular tone in the isolated perfused rabbit heart.
    Smith RE; Palmer RM; Bucknall CA; Moncada S
    Cardiovasc Res; 1992 May; 26(5):508-12. PubMed ID: 1446321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. L-arginine modulates aggregation and intracellular cyclic 3,5-guanosine monophosphate levels in human platelets: direct effect and interplay with antioxidative thiol agent.
    Anfossi G; Russo I; Massucco P; Mattiello L; Perna P; Tassone F; Trovati M
    Thromb Res; 1999 Jun; 94(5):307-16. PubMed ID: 10379819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of nitric oxide and guanosine 3',5'-cyclic monophosphate in mediating nonadrenergic, noncholinergic relaxation in guinea-pig pulmonary arteries.
    Liu SF; Crawley DE; Rohde JA; Evans TW; Barnes PJ
    Br J Pharmacol; 1992 Nov; 107(3):861-6. PubMed ID: 1335345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of nebivolol on human platelet aggregation.
    Falciani M; Rinaldi B; D'Agostino B; Mazzeo F; Rossi S; Nobili B; Rossi F; Filippelli A
    J Cardiovasc Pharmacol; 2001 Dec; 38(6):922-9. PubMed ID: 11707696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of brain nitric oxide synthase inhibition in vivo: ex vivo assays of nitric oxide synthase can give incorrect results.
    Salter M; Duffy C; Hazelwood R
    Neuropharmacology; 1995 Mar; 34(3):327-34. PubMed ID: 7543191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet effect of amlodipine: a possible mechanism through a nitric oxide-mediated process.
    Chou TC; Li CY; Yen MH; Ding YA
    Biochem Pharmacol; 1999 Nov; 58(10):1657-63. PubMed ID: 10535758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct electrochemical measurement of nitric oxide released from human platelets.
    Malinski T; Radomski MW; Taha Z; Moncada S
    Biochem Biophys Res Commun; 1993 Jul; 194(2):960-5. PubMed ID: 8343175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of nitric oxide synthase inhibition, nitric oxide and hydroperoxide on insulin release induced by various secretagogues.
    Panagiotidis G; Akesson B; Rydell EL; Lundquist I
    Br J Pharmacol; 1995 Jan; 114(2):289-96. PubMed ID: 7533613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of NG-substituted arginines on coronary vascular function after endotoxin.
    Winn MJ; Vallet B; Asante NK; Curtis SE; Cain SM
    J Appl Physiol (1985); 1993 Jul; 75(1):424-31. PubMed ID: 7690746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenosine increases human platelet levels of cGMP through nitric oxide: possible role in its antiaggregating effect.
    Anfossi G; Russo I; Massucco P; Mattiello L; Cavalot F; Balbo A; Trovati M
    Thromb Res; 2002 Jan; 105(1):71-8. PubMed ID: 11864710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of nitric oxide synthase attenuate human neutrophil chemotaxis in vitro.
    Belenky SN; Robbins RA; Rennard SI; Gossman GL; Nelson KJ; Rubinstein I
    J Lab Clin Med; 1993 Oct; 122(4):388-94. PubMed ID: 7693839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.